Skip to main content
. 2018 Nov 12;4(4):00035-2018. doi: 10.1183/23120541.00035-2018

FIGURE 3.

FIGURE 3

a) Plasma stem cell factor (SCF) increased after initiating pulmonary arterial hypertension (PAH)-specific therapy; between baseline and follow-up, changes in SCF (ΔSCF) correlated with changes in b) pulmonary vascular resistance (ΔPVR) and c) 6-min walking distance (Δ6MWD). *: p<0.05 comparing PAH at baseline versus follow-up.